Affiliation:
1. Division of Inflammation and Infection (II), Department of Biomedical and Clinical Sciences (BKV) Linköping University Linköping Sweden
2. Crown Princess Victoria Children's Hospital Linköping County of Östergötland Sweden
3. Department of Molecular Biosciences, The Wenner‐Gren Institute Stockholm University Stockholm Sweden
Abstract
AbstractObjectivesExtremely preterm (EPT; gestational week < 28 + 0, < 1000 g) neonates are vulnerable to infections and necrotising enterocolitis, important contributors to mortality and morbidity. However, knowledge regarding their immune maturation remains limited. We here investigated the longitudinal development of functional T‐cell capacity in EPT infants.MethodsPeripheral blood mononuclear cells were isolated at 14th and 28th day (D) and at gestational week 36 + 0 (Gw36) from EPT infants, participated in a randomised, double‐blind, placebo‐controlled study of Lactobacillus reuteri DSM 17938 probiotic supplementation. Blood collected from 25 full‐term (FT) infants at D14 was used as control. The secretion of immune mediators was determined through comprehensive Luminex panels after stimulation with human T‐cell activator CD3/CD28 beads.ResultsThe levels of many mediators were low in EPT infants at D14, whereas the secretion of several chemokines was higher in EPT than in FT infants. Furthermore, Th2:Th1 cytokine ratios were higher in EPT than in FT infants. Progressively elevated secretion of, for example, IFN‐γ, TNF and IL‐17A in EPT infants was observed from D14 to D28 and then at Gw36. Elevated levels were observed for many proinflammatory mediators at D28. Probiotic supplementation or perinatal factors (e.g. clinical chorioamnionitis, preeclampsia and delivery mode) did not influence the cytokine and chemokine responses.ConclusionsImmune mediators induced by T‐cell activation in EPT infants were mainly reduced at D14 and Th2 skewed compared to those in FT infants, but mostly recovered at Gw36, indicating immune maturation. Increased proinflammatory responses at D28 may be related to the heightened risk of severe immune‐associated complications seen in EPT infants.
Funder
Vetenskapsrådet
Svenska Sällskapet för Medicinsk Forskning
Stockholms Universitet
Linköpings Universitet
Region Östergötland
Insamlingsstiftelsen Cancer- och Allergifonden